Madan H. Jagasia
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Madan H. Jagasia

Hematology Oncology | Hematology
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
26 Years of Experience

Experienced in WT1-Related Wilms Tumor Syndromes
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Madan Jagasia is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Jagasia has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Nashville, TN 37232
Call: 615-322-3000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Other, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Enrollment Status: Completed
Publish Date: July 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis
T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis
Enrollment Status: Terminated
Publish Date: January 14, 2021
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Enrollment Status: Terminated
Publish Date: October 17, 2019
Intervention Type: Other
Ixazomib for Treatment of Chronic Graft vs. Host Disease
Ixazomib for Treatment of Chronic Graft vs. Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

181 Total Publications

Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
Journal: Cytotherapy
Published: November 10, 2024
View All 181 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian I. Rini
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian I. Rini
Hematology Oncology | Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Rini is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Rini is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy. Dr. Rini is currently accepting new patients.

Kathryn E. Beckermann
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kathryn E. Beckermann
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kathryn E. Beckermann
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

4488 Carothers Pkwy, Suite 300, 
Franklin, TN 
 (17.3 miles away)
615-591-4764
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Beckermann is a Hematologist Oncology specialist and a Hematologist in Franklin, Tennessee. Dr. Beckermann is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Adult Soft Tissue Sarcoma. Dr. Beckermann is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kristin Ancell
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kristin Ancell
Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (2.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristin Ancell is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Ancell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Melanoma, Neuroendocrine Tumor, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Gastrostomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jagasia's expertise for a condition
ConditionClose
  • Elite
  • Chronic Graft Versus Host Disease (cGvHD)
    Dr. Jagasia is
    Elite
    . Learn about Chronic Graft Versus Host Disease (cGvHD).
    See more Chronic Graft Versus Host Disease (cGvHD) experts
  • Graft Versus Host Disease (GvHD)
    Dr. Jagasia is
    Elite
    . Learn about Graft Versus Host Disease (GvHD).
    See more Graft Versus Host Disease (GvHD) experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Jagasia is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Jagasia is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Chronic Myelogenous Leukemia (CML)
    Dr. Jagasia is
    Distinguished
    . Learn about Chronic Myelogenous Leukemia (CML).
    See more Chronic Myelogenous Leukemia (CML) experts
  • Multiple Myeloma
    Dr. Jagasia is
    Distinguished
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Jagasia is
    Distinguished
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Primary Amyloidosis
    Dr. Jagasia is
    Distinguished
    . Learn about Primary Amyloidosis.
    See more Primary Amyloidosis experts
View All 8 Distinguished Conditions
  • Advanced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Jagasia is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Jagasia is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Aplastic Anemia
    Dr. Jagasia is
    Advanced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • Bone Marrow Transplant
    Dr. Jagasia is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Childhood Acute Myeloid Leukemia
    Dr. Jagasia is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Jagasia is
    Advanced
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
View All 11 Advanced Conditions
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Jagasia is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Acute Myelomonocytic Leukemia
    Dr. Jagasia is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Adenoid Cystic Carcinoma
    Dr. Jagasia is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Jagasia is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Jagasia is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Jagasia is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
View All 98 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved